Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases

Phase 1ATG-201Positive

AI Analysis

Summary

Antengene received clinical trial approval in Australia for the Phase 1 ATTRACT study of ATG-201, a CD19 x CD3 bispecific T cell engager for B cell-related autoimmune diseases.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Clinical trial approval received in Australia

Importance:5/10

Sentiment:

0.60

phase 1trial approvalAustraliaimmunologyautoimmune diseasebispecific antibody

Related Companies

$GBCYD $TRAX

Read the original article

Published by PR Newswire Biotech on August 25, 2026 12:30 AM

Read Original